As Tagrisso Launch Nears, AZ Pushes Stringent Prerequisites for Facilities, Doctors to Ensure Safety

Yuichiro Ohe, head of respiratory, NCC Hospital AstraZeneca K.K. has set rigorous prerequisites for medical institutions and physicians dealing with its soon-to-debut lung cancer drug Tagrisso (osimertinib) in a bid to pre-empt possible side effects such as interstitial pneumonia, company...read more